This is the kind of week I like to see. No flashy billion-dollar distractions—just real companies solving real problems and getting capital or access to keep executing. Business model and commercial progress still beat pure tech theater every time.
Trauma & Extremities Fixation
Meduloc (Website) — Series B Financing
Activity: Closed a $4M Series B financing round on August 6, 2026.
Led By: GenHenn Capital
Participants: Life Sciences Greenhouse Investments (LSGI), Ben Franklin Technology Partners of Southeastern PA, Broad Street Angels, existing and new investors, and former MLB All-Star Andre Ethier.
Technology: FDA-cleared, sterile, single-use, flexible nitinol intramedullary (IM) fracture fixation platform. Treats long-bone and small-bone fractures (metacarpal, radius, ulna, clavicle, fibula) across adult and pediatric populations while preserving surrounding anatomy and avoiding joint violation.
Use of Proceeds: Supports an early-August 2026 controlled alpha rollout with select surgeons and institutions; builds commercial infrastructure and clinical evidence.
Tiger’s Take: Smart, disciplined raise. Meduloc isn’t chasing the next robotic arm—they’re fixing the everyday frac...
